Analytical Data
-
基因名
L1/VACWR088, Vaccinia virus
- Application
-
别名
Virion membrane protein M25
-
种属
Vaccinia virus
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P07612
-
表达区间
2-183aa
-
分子量
24.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
L1/VACWR088 is a recombinant protein derived from the Vaccinia virus, which is a member of the Poxviridae family. The Vaccinia virus has been extensively studied due to its historical use as the vaccine for smallpox, a disease that has been eradicated through vaccination efforts. Research into L1/VACWR088 is driven by its potential applications in immunology and vaccine development. This recombinant protein serves as a valuable tool for understanding the mechanisms of viral pathogenesis and host immune responses. Additionally, Vaccinia virus proteins like L1/VACWR088 can be engineered for targeted vaccine strategies against various infectious diseases and even cancer. By studying the properties and functions of this recombinant protein, researchers aim to explore its efficacy in stimulating immune responses, which could lead to innovations in vaccine design and therapeutic interventions. The ongoing investigations into L1/VACWR088 exemplify the broader efforts to harness viral proteins for advancing public health and enhancing our understanding of viral interactions with the immune system. As such, the study of L1/VACWR088 holds promise for the development of next-generation vaccines and therapeutic strategies, emphasizing the relevance of Vaccinia virus research in contemporary biomedical science.
